Literature DB >> 8095787

Safety implications of the over-the-counter availability of H2-antagonists.

M Andersen1, J S Schou.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8095787     DOI： 10.2165/00002018-199308030-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  33 in total

1.  [Adverse effects of ulcer drugs before and after release of cimetidine, ranitidine and sucralfate for over-the-counter sale].

Authors:  M Andersen; J S Schou
Journal:  Ugeskr Laeger       Date:  1991-05-13

Review 2.  Over-the-counter drugs. The issues.

Authors:  H Cranz
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

3.  Pharmacists' evaluations of the nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin.

Authors:  S Madhavan; S W Schondelmeyer
Journal:  Am J Hosp Pharm       Date:  1989-12

4.  [Basis for ulcus therapy in general practice].

Authors:  M Gormsen; K S Jensen; P Matzen; O Bonnevie
Journal:  Ugeskr Laeger       Date:  1988-09-12

5.  Over the counter sales of histamine-2 receptor antagonists.

Authors:  H Petersen
Journal:  Scand J Gastroenterol Suppl       Date:  1988

Review 6.  Dyspepsia: a dilemma for doctors?

Authors:  R V Heatley; B J Rathbone
Journal:  Lancet       Date:  1987-10-03       Impact factor: 79.321

7.  Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users.

Authors:  H Møller; A Nissen; J Mosbech
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

8.  Cimetidine toxicity: an assessment of 881 cases.

Authors:  E P Krenzelok; T Litovitz; K P Lippold; C F McNally
Journal:  Ann Emerg Med       Date:  1987-11       Impact factor: 5.721

9.  Gastric cancer--delay in diagnosis and its causes.

Authors:  T Mikulin; J D Hardcastle
Journal:  Eur J Cancer Clin Oncol       Date:  1987-11

10.  Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapy.

Authors:  J M Richter; G A Colditz; D M Huse; T E Delea; G Oster
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965
View more
  8 in total

Review 1.  Benefits and risks of self medication.

Authors:  C M Hughes; J C McElnay; G F Fleming
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases?

Authors:  S Holt
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 3.  Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.

Authors:  J E Frampton; D McTavish
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

Review 4.  Formulary management of drugs for cancer-associated hypercalcaemia.

Authors:  S J Gallacher
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

5.  Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.

Authors:  R F Tasch; R Goeree; C J Henke; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 6.  Polypharmacy. Pharmacokinetic perspectives.

Authors:  P K Honig; L R Cantilena
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

7.  Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.

Authors:  R H Hunt
Journal:  CMAJ       Date:  1996-01-01       Impact factor: 8.262

8.  Are H2 receptor antagonists safe over the counter drugs?

Authors:  M Andersen; J S Schou
Journal:  BMJ       Date:  1994 Aug 20-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.